Whole blood leukodepletion and platelet filter

• US 5,647,985 A
• Filed: 10/17/1994
• Issued: 07/15/1997
• Est. Priority Date: 10/17/1994
• Status: Expired due to Term

• Current Assignee: Fenwal Incorporated (Fresenius SE & Co. KGaA)
• Original Assignee: Baxter International Inc.
• Inventors: Johnson, Richard J., Ung-Chhun, Neng S.
• Primary Examiner(s): KIM, SUN U
• Application Number:
  US08/323,559
• Time in Patent Office: 1,002 Days
• Field of Search: 210/503, 210/504, 210/506, 210/507, 210/508, 210/505, 422/101, 428/357, 428/361, 428/365, 428/378, 428/375, 427/501, 427/541, 427/170, 427/244, 427/258, 427/379, 427/372.2, 427/384, 427/394, 427/385.5, 427/389.9, 427/402, 427/412, 427/407.1, 427/417, 427/513
• US Class Current: 210/504
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0057 retained by adsorption
• CPC Class Codes: A61M 2202/0439 White blood cells; Leucocytes lymphocytes A61M2202/0407
• CPC Class Codes: B01D 39/1623 of synthetic origin
• CPC Class Codes: Y10T 428/2915 including textile, cloth or fabric
• CPC Class Codes: Y10T 436/25375 Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
• CPC Class Codes: Y10T 436/255 including use of a solid sorbent, semipermeable membrane, or liquid extraction

Abstract

Novel blood cell fractionation means utilizes conventional filters coated with high molecular weight polyethylene oxide derivatives crosslinked to prevent leaching from filter surfaces. These fractionation means have a special efficacy in binding white blood cells from whole blood while simultaneously allowing red cells and platelets to pass in the effluent phase.

Claims

1. Blood cell fractionation means comprising:

a filter matrix having a fibrous structure, and

a coating thereon comprising an insitu condensation product of a first electrophilically active, high molecular weight polyalkylene oxide and a second high molecular weight polyalkylene oxide derivative selected from the group consisting of tetraaminopolyalkylene oxide , a bifunctional dihydroxy-polyalkylene oxide derivative and a bifunctional diamino-polyalkylene oxide derivative.

2. The blood cell fractionation means of claim 1 wherein said first electrophilically active, high molecular weight polyalkylene oxide has the general structure Y-PEO-R-PEO-Y wherein Y is a reactive moiety selected from the group consisting of oxycarbonylimidazole;

tresyl-, tosyl-, N-hydroxysuccinimidyl-, and p-nitrophenyl-activated esters;

acrylates;

glycidyl ethers; and

aldehydes, wherein R is a spacer selected from the group consisting of bisphenol A and bisphenol B, and wherein PEO is a high molecular weight polyalkylene oxide.

3. Blood cell fractionation means comprising

a filter matrix having a fibrous structure, and

a coating thereon comprising an irradiated condensation product of a high molecular weight tetraacrylatepolyalkylene oxide.

4. Blood cell fractionation means comprising:

a filter matrix having a fibrous structure, and

a coating thereon comprising an isopolymer of a high molecular weight tetraacrylatepolyalkylene oxide, polymerized by exposure to radiation.